Now in press & online @ Ophthalmology, the journal of the American Academy of Ophthalmology, the first phase 3 trial to evaluate suprachoroidal injection for treatment of an ocular disease… https://t.co/hgCc9WHHdu Source by Thomas Ciulla, MD, MBA Return to main website.
Disruption brings harmony in biotech: The rise of anti-VEGF therapy shows what industry, academia, private practice can create together. https://t.co/WwBCk4kkr8 Source by Thomas Ciulla, MD, MBA Return to main website.
RT @OphthalmicPro: Are you curious about gene therapy? Check out Dr. Thomas Ciulla’s article at https://t.co/82jHtEhRGq #ophthalmology #eye…
Source by Thomas Ciulla, MD, MBA
RT @RetinalPhys: Clearside Biomedical said it has done significant preclinical testing of the anti-VEGF axitinib and plans to begin a clini… Source by Thomas Ciulla, MD, MBA Return to main website.
In San Francisco this week for the JP Morgan Healthcare Conference #jpm2020. Looking forward to connecting with old friends and colleagues. Please reach out if you want to catch up. Source by Thomas Ciulla, MD, MBA Return to main website.
RT @OphthalmicPro: Gene therapy has gotten some major buzz in the medical community of late. In this issue, Dr. Thomas Ciulla gives us a pr…
Source by Thomas Ciulla, MD, MBA
Vascular alterations in macular degeneration and diabetic retinopathy, reviewed in this chapter we just published…. https://t.co/X0OzpZAMga Source by Thomas Ciulla, MD, MBA Return to main website.